A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome.

Trial Profile

A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Afacifenacin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Dainippon Sumitomo Pharma; Sunovion Pharmaceuticals
  • Most Recent Events

    • 21 Nov 2012 New source identified (German Clinical Trials Register record: DRKS00004137).
    • 04 Aug 2008 Status change from in progress to completed, according to clinicaltrials.gov.
    • 25 Jun 2008 The expected completion date for this trial is now 1 Jul 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top